Pharmaids Pharmaceuticals (524572) Q4 24/25 earnings summary

Executive summary

• Audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, were approved, with audit reports issued without modifications.

• The group operates in a single segment: Contract Research and Manufacturing Services.

Financial highlights

• Standalone revenue from operations for FY25 was Rs 234.09 lakhs, up from Rs 2.78 lakhs in FY24; consolidated revenue was Rs 1,944.74 lakhs, up from Rs 1,511.21 lakhs year-over-year.

• Standalone net loss for FY25 was Rs (727.92) lakhs, compared to Rs (494.98) lakhs in FY24; consolidated net loss was Rs (1,350.51) lakhs, compared to Rs (1,184.31) lakhs year-over-year.

• Standalone EPS for FY25 was Rs (2.06), compared to Rs (2.18) in FY24; consolidated EPS was Rs (3.56), compared to Rs (3.05) in FY24.

• Standalone total income for FY25 was Rs 335.98 lakhs, up from Rs 82.27 lakhs in FY24; consolidated total income was Rs 1,955.14 lakhs, up from Rs 1,599.03 lakhs year-over-year.

Outlook and guidance

• No forward-looking guidance or projections were provided; focus remains on contract research and manufacturing services.